Overview of EVPLL: Potential Drug Target Or Biomarker (G645027)

Target Name: EVPLL

NCBI ID: G645027

EVPLL

Other Name(s): EVPLL_HUMAN | Envoplakin-like protein | Envoplakin like | envoplakin like

Overview of EVPLL: Potential Drug Target Or Biomarker

EvplLL (EVPLL-HUMAN) is a protein that is expressed in human tissues and has been shown to play a role in various biological processes. The research on EVPLL has primarily focused on its potential role as a drug target or biomarker. In this article, we will provide an overview of EVPLL, its expression, function, and potential as a drug target.

Expression and Function

EVPLL is a member of the Tissue Factor Processing (TFPC) family, which is involved in the processing and presentation of extracellular matrix (ECM) proteins to the cell surface. EVPLL is a 21-kDa protein that is expressed in various human tissues, including muscle, pancreas, and heart.

EVPLL functions as a negative regulator of the transcription factor, NF-kappa-B. NF-kappa-B is a protein that plays a role in cell signaling and is involved in various physiological processes, including inflammation, pain, and survival. EVPLL can inhibit the activity of NF-kappa-B and prevent it from activating target genes that are involved in inflammation, pain, and survival.

EVPLL has also been shown to play a role in the regulation of cellular processes such as cell adhesion, migration, and invasion. EVPLL can interact with various cell surface molecules, including cadherins, integrins, and E-cadherins, and is involved in the regulation of their functions.

Potential as a Drug Target

The potential use of EVPLL as a drug target is based on its involvement in various biological processes and its ability to regulate cellular processes. EVPLL has been shown to be a good candidate for anti-inflammatory and anti-cancer drugs.

One of the main reasons for the potential use of EVPLL as a drug target is its ability to regulate the activity of NF-kappa-B. NF-kappa-B is involved in the regulation of various cellular processes, including inflammation, pain, and survival. EVPLL can inhibit the activity of NF-kappa-B and prevent it from activating target genes that are involved in inflammation, pain, and survival. This suggests that EVPLL may be an effective target for drugs that are designed to inhibit NF-kappa-B activity.

Another reason for the potential use of EVPLL as a drug target is its involvement in the regulation of cell adhesion, migration, and invasion. EVPLL can interact with various cell surface molecules, including cadherins, integrins, and E-cadherins, and is involved in the regulation of their functions. This suggests that EVPLL may be an effective target for drugs that are designed to modulate these processes.

EVPLL has also been shown to play a role in the regulation of cellular processes such as cell death, angiogenesis, and inflammation. EVPLL can interact with various cellular signaling pathways, including the TGF-β pathway, and is involved in the regulation of cell proliferation, apoptosis, and angiogenesis. This suggests that EVPLL may be an effective target for drugs that are designed to inhibit these processes.

Conclusion

In conclusion, EVPLL is a protein that is expressed in human tissues and has been shown to play a role in various biological processes. The research on EVPLL has primarily focused on its potential role as a drug target or biomarker. EVPLL has been shown to function as a negative regulator of the transcription factor, NF-kappa-B, and to play a role in the regulation of cellular processes such as cell adhesion, migration, and invasion. The potential use of EVPLL as a drug target is based on its ability to inhibit the activity of NF-kappa-B and prevent it from activating target genes that are involved in inflammation, pain, and survival. Further research is needed to fully understand the potential of EVPLL as a drug target.

Protein Name: Envoplakin Like

The "EVPLL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EVPLL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets